Pesquisa | BVS IEC

1.

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Smith, Matthew R; Hussain, Maha; Saad, Fred; Fizazi, Karim; Sternberg, Cora N; Crawford, E David; Kopyltsov, Evgeny; Park, Chandler H; Alekseev, Boris; Montesa-Pino, Álvaro; Ye, Dingwei; Parnis, Francis; Cruz, Felipe; Tammela, Teuvo L J; Suzuki, Hiroyoshi; Utriainen, Tapio; Fu, Cheng; Uemura, Motohide; Méndez-Vidal, María J; Maughan, Benjamin L; Joensuu, Heikki; Thiele, Silke; Li, Rui; Kuss, Iris; Tombal, Bertrand.

N Engl J Med ; 386(12): 1132-1142, 2022 03 24.

Artigo em Inglês | MEDLINE | ID: mdl-35179323

2.

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Crawford, E David; Hafron, Jason M; Debruyne, Frans; Wallis, Christopher; Chang, Steven; Garnick, Marc B.

J Urol ; 211(1): 63-70, 2024 Jan.

Artigo em Inglês | MEDLINE | ID: mdl-37796473

3.

Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.

Crawford, E David; Hafron, Jason M; Tagawa, Scott T; Twardowski, Przemyslaw W; Harris, Richard G; Moul, Judd W; Keane, Thomas E; Concepcion, Raoul S; Higano, Celestia S; Gordan, Lucio N; Petrylak, Daniel P; Cross, Chaundre K; Kader, A Karim; Shore, Neal D.

J Urol ; 205(2): 554-560, 2021 02.

Artigo em Inglês | MEDLINE | ID: mdl-33090917

4.

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.

Shore, Neal D; Antonarakis, Emmanuel S; Cookson, Michael S; Crawford, E David; Morgans, Alicia K; Albala, David M; Hafron, Jason; Harris, Richard G; Saltzstein, Daniel; Brown, Gordon A; Henderson, Jonathan; Lowentritt, Benjamin; Spier, Jeffrey M; Concepcion, Raoul.

Prostate ; 80(6): 527-544, 2020 05.

Artigo em Inglês | MEDLINE | ID: mdl-32130741

5.

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.

Crawford, E David; Twardowski, Przemyslaw W; Concepcion, Raoul S; Hafron, Jason M; Harris, Richard G; Moul, Judd W; Gordan, Lucio N; Petrylak, Daniel P; Atkinson, Stuart N; Boldt-Houle, Deborah M; Keane, Thomas E; Higano, Celestia S; Henderson, R Jonathan; Kader, A Karim; Hussain, Maha H; Shore, Neal D.

J Urol ; 203(4): 743-750, 2020 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-31580749

6.

69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.

Gonzalez-Ochoa, Eduardo; Verduzco-Aguirre, Haydee; Crawford, E David; Bourlon, María T.

Oncology (Williston Park) ; 34(4)2020 04 10.

Artigo em Inglês | MEDLINE | ID: mdl-32293692

7.

The role of FSH and LH in prostate cancer and cardiometabolic comorbidities.

Crawford, E David; Schally, Andrew V.

Can J Urol ; 27(2): 10167-10173, 2020 04.

Artigo em Inglês | MEDLINE | ID: mdl-32333736

8.

Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.

Stanton, Whitney N; Crawford, E David; Arangua, Paul B; La Rosa, Francisco G; van Bokhoven, Adrie; Lucia, M Scott; Poage, Wendy L; Partin, Alan; Maroni, Paul; Werahera, Priya N.

Can J Urol ; 27(1): 10080-10085, 2020 02.

Artigo em Inglês | MEDLINE | ID: mdl-32065862

9.

Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.

Crawford, E David; Andriole, Gerald; Freedland, Stephen J; Garnick, Marc; Gomella, Leonard G; Henderson, Jonathan; Higano, Celestia Tia; Kader, Andrew Karim; Kane, Christopher; Keane, Thomas E; Koo, Phillip J; Petrylak, Daniel P; Reiter, Robert E; Slovin, Susan F; Yu, Evan Y.

Can J Urol ; 27(5): 10352-10362, 2020 10.

Artigo em Inglês | MEDLINE | ID: mdl-33049187

10.

Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Garnick, Marc B; Hafron, Jason; Crawford, E David.

J Urol ; 211(3): 482, 2024 Mar.

Artigo em Inglês | MEDLINE | ID: mdl-38179977

11.

The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.

Stone, Nelson N; Crawford, E David; Skouteris, Vassilios M; Arangua, Paul; Metsinis, Panagiotis-Marios; Lucia, M Scott; La Rosa, Francisco G; Werahera, Priya N.

J Urol ; 202(2): 264-271, 2019 08.

Artigo em Inglês | MEDLINE | ID: mdl-30835628

12.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Crawford, E David; Koo, Phillip J; Shore, Neal; Slovin, Susan F; Concepcion, Raoul S; Freedland, Stephen J; Gomella, Leonard G; Karsh, Lawrence; Keane, Thomas E; Maroni, Paul; Penson, David; Petrylak, Daniel P; Ross, Ashley; Mouraviev, Vlad; Reiter, Robert E; Divgi, Chaitanya; Yu, Evan Y.

J Urol ; 201(4): 682-692, 2019 04.

Artigo em Inglês | MEDLINE | ID: mdl-30077557

13.

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

Pinsky, Paul F; Miller, Eric; Prorok, Philip; Grubb, Robert; Crawford, E David; Andriole, Gerald.

BJU Int ; 123(5): 854-860, 2019 05.

Artigo em Inglês | MEDLINE | ID: mdl-30288918

14.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning, Harry J; Gulati, Roman; Moss, Sue M; Hugosson, Jonas; Pinsky, Paul F; Berg, Christine D; Auvinen, Anssi; Andriole, Gerald L; Roobol, Monique J; Crawford, E David; Nelen, Vera; Kwiatkowski, Maciej; Zappa, Marco; Luján, Marcos; Villers, Arnauld; de Carvalho, Tiago M; Feuer, Eric J; Tsodikov, Alex; Mariotto, Angela B; Heijnsdijk, Eveline A M; Etzioni, Ruth.

Cancer ; 124(6): 1197-1206, 2018 03 15.

Artigo em Inglês | MEDLINE | ID: mdl-29211316

15.

Editorial Comment.

Javier-DesLoges, Juan; Bagrodia, Aditya; Crawford, E David; Kane, Christopher J.

J Urol ; 210(4): 637-638, 2023 10.

Artigo em Inglês | MEDLINE | ID: mdl-37527395

16.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Ryan, Charles J; Crawford, E David; Shore, Neal D; Underwood, Willie; Taplin, Mary-Ellen; Londhe, Anil; Francis, Peter St John; Phillips, Jennifer; McGowan, Tracy; Kantoff, Philip W.

J Urol ; 200(2): 344-352, 2018 08.

Artigo em Inglês | MEDLINE | ID: mdl-29630978

17.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Crawford, E David; Schellhammer, Paul F; McLeod, David G; Moul, Judd W; Higano, Celestia S; Shore, Neal; Denis, Louis; Iversen, Peter; Eisenberger, Mario A; Labrie, Fernand.

J Urol ; 200(5): 956-966, 2018 11.

Artigo em Inglês | MEDLINE | ID: mdl-29730201

18.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov, Alex; Gulati, Roman; Heijnsdijk, Eveline A M; Pinsky, Paul F; Moss, Sue M; Qiu, Sheng; de Carvalho, Tiago M; Hugosson, Jonas; Berg, Christine D; Auvinen, Anssi; Andriole, Gerald L; Roobol, Monique J; Crawford, E David; Nelen, Vera; Kwiatkowski, Maciej; Zappa, Marco; Luján, Marcos; Villers, Arnauld; Feuer, Eric J; de Koning, Harry J; Mariotto, Angela B; Etzioni, Ruth.

Ann Intern Med ; 167(7): 449-455, 2017 Oct 03.

Artigo em Inglês | MEDLINE | ID: mdl-28869989

19.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Pinsky, Paul F; Prorok, Philip C; Yu, Kelly; Kramer, Barnett S; Black, Amanda; Gohagan, John K; Crawford, E David; Grubb, Robert L; Andriole, Gerald L.

Cancer ; 123(4): 592-599, 2017 Feb 15.

Artigo em Inglês | MEDLINE | ID: mdl-27911486

20.

Editorial Comment.

Crawford, E David.

J Urol ; 208(2): 324, 2022 08.

Artigo em Inglês | MEDLINE | ID: mdl-35510427

BVS IEC

Instituto Evandro Chagas

Configurar filtros

Sua seleção (0)

Formato de exportação:

Exportar:

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.

Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data.

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines.

The Impact of Late Luteinizing Hormone-Releasing Hormone Agonist Dosing on Testosterone Suppression in Patients with Prostate Cancer: An Analysis of United States Clinical Data.

69-Year-Old Man With Castration-Resistant Prostate Cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.

The role of FSH and LH in prostate cancer and cardiometabolic comorbidities.

Assessment of high-grade prostate cancer risk using prostate cancer biomarkers.

Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.

Reply: Cardiovascular Risk in Prostate Cancer Patients Using Luteinizing Hormone-Releasing Hormone Agonists or a Gonadotropin-Releasing Hormone Antagonist.

The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III).

Extended follow-up for prostate cancer incidence and mortality among participants in the Prostate, Lung, Colorectal and Ovarian randomized cancer screening trial.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

Editorial Comment.

The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer.

Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years.

Editorial Comment.